Prevalence of elevated troponin I in end-stage renal disease patients receiving hemodialysis

Michael W. Donnino, Varnada Karriem-Norwood, Emanuel P. Rivers, Ajay Gupta, H. Bryant Nguyen, Gordon Jacobsen, James McCord, Michael C. Tomlanovich

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives Patients with end-stage renal disease (ESRD) who are receiving hemodialysis have an increased incidence of atherosclerotic heart disease. Currently, there is considerable controversy regarding the significance of elevated cardiac troponin I (cTnI) levels in patients with ESRD. The objective of this study was to examine the prevalence of elevated cTnI levels in asymptomatic patients with ESRD on hemodialysis. Methods This was a prospective cohort study at an urban hospital outpatient dialysis center. Serum was collected pre- and postdialysis from patients on dialysis at this center over a two-week period. Samples were batched and analyzed for cTnI using the Asxym fluorescent antibody test. An elevated cTnI level was defined as >0.8 ng/dL. Results Predialysis cTnI levels ranged from <0.1 to 0.7 ng/dL, and postdialysis cTnI levels ranged from <0.1 to 0.6 ng/dL. None of the patients had a cTnI level >0.8 ng/dL. Conclusions cTnI levels are not falsely elevated in patients with ESRD on hemodialysis. In a patient with ESRD, myocardial injury should be suspected if his or her cTnI level is >0.8 ng/dL.

Original languageEnglish
Pages (from-to)979-981
Number of pages3
JournalAcademic Emergency Medicine
Volume11
Issue number9
DOIs
StatePublished - Sep 2004

ASJC Scopus Subject Areas

  • Emergency Medicine

Keywords

  • acute coronary syndrome
  • biomarkers
  • cardiac enzymes
  • dialysis
  • renal failure
  • troponin

Cite this